OSE Pharma SA (PA:OSE) — Stock Price
OSE Pharma SA (PA:OSE) is currently trading at €3.23 EUR, down 3.00% today. Over the past 52 weeks, shares have ranged between €3.02 and €7.20. This page tracks OSE Pharma SA's live share price on the PA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see OSE company net worth.
OSE Pharma SA (OSE) Stock Price Chart — Daily History & Trading Volume
The chart below tracks OSE Pharma SA's daily closing share price and trading volume on the PA exchange over the past year, giving a clear view of recent price momentum and liquidity.
OSE Pharma SA Income Statement — Revenue, Profit & Earnings by Year
OSE Pharma SA's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | €69.88 Million | €2.23 Million | €18.30 Million | €26.31 Million | €10.42 Million |
| Cost of Revenue | €69.88 Million | — | — | — | €-1.00K |
| Gross Profit | €69.88 Million | €2.23 Million | €18.30 Million | €26.31 Million | €10.42 Million |
| Research & Development | €32.85 Million | €17.16 Million | €26.89 Million | €30.55 Million | €22.36 Million |
| SG&A | €6.26 Million | €5.96 Million | €6.59 Million | €8.50 Million | €4.70 Million |
| Total Operating Expenses | €41.52 Million | €25.21 Million | €36.78 Million | €42.93 Million | €29.41 Million |
| Operating Income | €43.73 Million | €-22.99 Million | €-18.48 Million | €-16.62 Million | €-18.99 Million |
| EBITDA | €41.20 Million | €-17.50 Million | €-13.11 Million | €-13.72 Million | €-18.24 Million |
| EBIT | €37.83 Million | €-21.03 Million | €-16.67 Million | €-16.38 Million | €-18.97 Million |
| Interest Expense | €3.30 Million | €2.27 Million | €1.37 Million | €836.00K | €273.00K |
| Income Before Tax | €39.83 Million | €-23.22 Million | €-23.45 Million | €-21.56 Million | €-19.25 Million |
| Income Tax Expense | €2.39 Million | €-219.00K | €-5.69 Million | €-4.71 Million | €-2.69 Million |
| Net Income | €37.45 Million | €-23.00 Million | €-17.76 Million | €-16.85 Million | €-16.55 Million |
OSE Pharma SA Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes OSE Pharma SA's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | €123.96 Million | €82.05 Million | €91.67 Million | €101.52 Million | €96.85 Million |
| Total Current Assets | €69.93 Million | €30.48 Million | €37.20 Million | €44.21 Million | €39.83 Million |
| Cash & Equivalents | €9.31 Million | €12.57 Million | €7.11 Million | €33.58 Million | €29.37 Million |
| Short-term Investments | €42.37 Million | — | — | €-226.00K | €-454.00K |
| Net Receivables | €4.14 Million | €1.80 Million | €8.13 Million | €1.59 Million | €1.75 Million |
| Inventory | — | €-982.00K | — | €2.96 Million | — |
| Property, Plant & Equipment | €3.42 Million | €4.07 Million | €4.98 Million | €5.44 Million | €3.79 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €60.15 Million | €59.08 Million | €59.12 Million | €53.99 Million | €35.61 Million |
| Total Current Liabilities | €20.22 Million | €18.80 Million | €16.27 Million | €16.76 Million | €14.13 Million |
| Long-term Debt | €35.66 Million | €35.51 Million | €37.23 Million | €30.80 Million | €16.55 Million |
| Net Debt | €29.39 Million | €27.13 Million | €19.17 Million | €3.55 Million | €-9.85 Million |
| Total Stockholder Equity | €63.81 Million | €22.82 Million | €32.55 Million | €47.89 Million | €61.24 Million |
| Retained Earnings | €-17.87 Million | €-23.00 Million | €-35.89 Million | €-21.11 Million | €-7.49 Million |
OSE Pharma SA Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how OSE Pharma SA generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | €48.44 Million | €-19.76 Million | €-18.25 Million | €-9.92 Million | €-19.55 Million |
| Capital Expenditures | €77.00K | €232.00K | €274.00K | €472.00K | €210.00K |
| Free Cash Flow | €48.36 Million | €-20.00 Million | €-18.53 Million | €-10.39 Million | €-19.76 Million |
| Investing Cash Flow | €-46.91 Million | €-507.00K | €26.00K | €-827.00K | €-504.00K |
| Financing Cash Flow | €-3.46 Million | €13.32 Million | €10.27 Million | €14.96 Million | €23.58 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €2.09 Million | €1.75 Million | €2.73 Million | €3.77 Million | €2.28 Million |
| Depreciation | €6.26 Million | €3.47 Million | €3.54 Million | €2.61 Million | €730.00K |
| Change in Cash | €-1.93 Million | €-6.95 Million | €-7.96 Million | €4.21 Million | €3.53 Million |
OSE Pharma SA Earnings History — EPS Actual vs. Analyst Estimates
Track OSE Pharma SA's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 26, 2026 | — | — | — |
| May 01, 2025 | -0.90 | 0.00 | — |
| Mar 25, 2025 | — | — | — |
| Apr 27, 2023 | -0.85 | — | — |
| Sep 22, 2022 | -0.11 | — | — |
| Mar 30, 2022 | -0.93 | 0.00 | — |
| Aug 26, 2021 | -0.64 | 0.00 | — |
| Mar 29, 2021 | -0.84 | 0.00 | — |